Adropin as a Marker in Type 2 Diabetes: Insights Into Diabetic Kidney Disease and Chronic Heart Failure
The study demonstrated that serum adropin levels decline progressively with worsening cardiorenal-metabolic parameters. These findings reinforce the role of adropin as a sensitive marker of endothelial and metabolic dysfunction, especially in patients with coexisting T2DM, DKD, and CHF. Given its strong correlation with markers of glycemic control, renal impairment, and inflammation, adropin may serve as a noninvasive biomarker for early detection and risk stratification.
Authors
- Abhishek Singh (ORCID: https://orcid.org/0000-0003-1207-2581)
- Gyanendra Kumar Sonkar (ORCID: https://orcid.org/0000-0002-0813-5466)
- Medhavi Gautam
- Vivek Bhosale (ORCID: https://orcid.org/0000-0002-2729-266X)
- Deepak Bhagchandani (ORCID: https://orcid.org/0009-0006-9672-4813)
- Satyendra Kumar Sonkar (ORCID: https://orcid.org/0000-0002-6350-9299)
- Madhu Agrawal (ORCID: https://orcid.org/0000-0001-5657-1062)
- Akshyaya Kumar Pradhan (ORCID: https://orcid.org/0000-0002-2360-7580)
- Satish Kumar (ORCID: https://orcid.org/0000-0002-5793-5515)
Institutions
- Central Drug Research Institute (IN)
- King George's Medical University (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-09-03
- DOI
- https://doi.org/10.7759/cureus.91572
- Primary Topic
- Adipose Tissue and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Indian Council of Medical Research
- Central Drug Research Institute